HC Wainwright Issues Pessimistic Estimate for COGT Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - HC Wainwright reduced their Q3 2025 earnings estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, July 8th. HC Wainwright analyst R. Burns now forecasts that the technology company will earn ($0.60) per share for the quarter, down from their prior estimate of ($0.59). HC Wainwright has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($2.93) EPS.

Other research analysts have also issued research reports about the company. Jefferies Financial Group increased their price target on Cogent Biosciences from $23.00 to $28.00 and gave the stock a "buy" rating in a report on Monday. JPMorgan Chase & Co. boosted their price target on shares of Cogent Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a research note on Tuesday, June 17th. Guggenheim reissued a "buy" rating and set a $17.00 target price on shares of Cogent Biosciences in a research report on Tuesday. Finally, Wedbush reiterated a "neutral" rating and set a $10.00 price target on shares of Cogent Biosciences in a research note on Monday, June 30th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Cogent Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Cogent Biosciences Price Performance

Shares of NASDAQ COGT traded up $0.45 during trading on Thursday, hitting $10.85. 6,140,974 shares of the company traded hands, compared to its average volume of 1,559,930. The business's fifty day moving average is $6.33 and its 200 day moving average is $6.79. Cogent Biosciences has a fifty-two week low of $3.72 and a fifty-two week high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Institutional Trading of Cogent Biosciences

Several hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in Cogent Biosciences in the first quarter valued at approximately $36,000. CWM LLC raised its stake in shares of Cogent Biosciences by 11,869.9% in the first quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC bought a new position in shares of Cogent Biosciences during the 4th quarter worth $78,000. Hsbc Holdings PLC purchased a new stake in Cogent Biosciences in the 4th quarter worth about $81,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Cogent Biosciences during the fourth quarter valued at about $88,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.